Department of Respiratory and Sleep Medicine, Queensland Children's Hospital, Centre for Children's Health Research, Queensland University of Technology, Brisbane, QLD, Australia.
Academic Department of Paediatrics, The Royal Alexandra Children's Hospital, Brighton and Sussex Medical School, Brighton, UK.
Respirology. 2021 Mar;26(3):241-248. doi: 10.1111/resp.13950. Epub 2020 Oct 12.
Long-term data on children with PBB has been identified as a research priority. We describe the 5-year outcomes for children with PBB to ascertain the presence of chronic respiratory disease (bronchiectasis, recurrent PBB and asthma) and identify the risk factors for these.
Prospective cohort study was undertaken at the Queensland Children's Hospital, Brisbane, Australia, of 166 children with PBB and 28 controls (undergoing bronchoscopy for symptoms other than chronic wet cough). Monitoring was by monthly contact via research staff. Clinical review, spirometry and CT chest were performed as clinically indicated.
A total of 194 children were included in the analysis. Median duration of follow-up was 59 months (IQR: 50-71 months) post-index PBB episode, 67.5% had ongoing symptoms and 9.6% had bronchiectasis. Significant predictors of bronchiectasis were recurrent PBB in year 1 of follow-up (OR = 9.6, 95% CI: 1.8-50.1) and the presence of Haemophilus influenzae in the BAL (OR = 5.1, 95% CI: 1.4-19.1). Clinician-diagnosed asthma at final follow-up was present in 27.1% of children with PBB. A significant BDR (FEV improvement >12%) was obtained in 63.5% of the children who underwent reversibility testing. Positive allergen-specific IgE (OR = 14.8, 95% CI: 2.2-100.8) at baseline and bronchomalacia (OR = 5.9, 95% CI: 1.2-29.7) were significant predictors of asthma diagnosis. Spirometry parameters were in the normal range.
As a significant proportion of children with PBB have ongoing symptoms at 5 years, and outcomes include bronchiectasis and asthma, they should be carefully followed up clinically. Defining biomarkers, endotypes and mechanistic studies elucidating the different outcomes are now required.
长期随访儿童持久性细支气管炎(PBB)患者的数据被认为是研究的重点。我们描述了 PBB 患儿的 5 年结局,以确定是否存在慢性呼吸道疾病(支气管扩张、反复性 PBB 和哮喘),并确定这些疾病的危险因素。
在澳大利亚布里斯班昆士兰儿童医院进行了一项前瞻性队列研究,纳入了 166 例 PBB 患儿和 28 例对照组(因慢性湿咳以外的症状行支气管镜检查)。通过研究人员每月联系进行监测。根据临床需要进行临床评估、肺量测定和胸部 CT。
共有 194 例患儿纳入分析。中位随访时间为索引性 PBB 发作后 59 个月(IQR:50-71 个月),67.5%患儿仍有症状,9.6%患儿存在支气管扩张。随访第 1 年反复性 PBB(OR=9.6,95%CI:1.8-50.1)和 BAL 中存在流感嗜血杆菌(OR=5.1,95%CI:1.4-19.1)是支气管扩张的显著预测因素。在最终随访时,27.1%的 PBB 患儿被诊断为哮喘。接受气道反应性检查的患儿中,63.5%获得了显著的 BDR(FEV1 改善>12%)。基线时存在变应原特异性 IgE 阳性(OR=14.8,95%CI:2.2-100.8)和支气管软化(OR=5.9,95%CI:1.2-29.7)是哮喘诊断的显著预测因素。肺量测定参数在正常范围内。
由于相当一部分 PBB 患儿在 5 年后仍有症状,且结局包括支气管扩张和哮喘,因此需要对其进行密切的临床随访。现在需要定义生物标志物、表型和阐明不同结局的机制研究。